SynCore
杏國新藥股份有限公司
SynCore is a Taiwan TPEx-listed biotechnology company, as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| EndoTAG-1 | — | Phase 3; completed | Metastatic Pancreas Cancer; Locally Advanced Pancreatic Cancer; Pancreatic Adenocarcinoma | France, Hungary, Israel, Russia, South Korea, Taiwan, United States | 2023-05-06 | Trial registry |
| SCB01A | — | Phase 2; terminated | Head and Neck Neoplasms | Taiwan | 2023-06-05 | Trial registry |
Key events
No verified events in the past twelve months.
Related Drugnews articles
No related articles in this language.